^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Meiyouheng (becotatug vedotin)

    i
    Other names: MRG003, MRG-003, MRG 003
    Company:
    Lepu Med
    Drug class:
    Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    Related drugs:
    1m
    MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Dongguan People's Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Loqtorzi (toripalimab-tpzi) • Meiyouheng (becotatug vedotin)
    2ms
    Comprehensive analysis of antibody-drug conjugate (ADC) targets in adenoid cystic carcinoma: examining antigen expression in relation to clinicopathological features, prognosis, and initial therapeutic outcomes. (PubMed, Transl Oncol)
    Importantly, early clinical studies demonstrated that the EGFR-targeted ADC MRG003 and the TROP2-targeted ADC Sac-TMT showed notable efficacy in patients with refractory ACC and high expression of these targets. This pioneering study introduces a biomarker-based stratification system, categorizing ACC patients by histological subtype and target expression profiles, EGFR/TROP2 for non-solid ACC and B7-H4/Nectin-4 for solid ACC, to inform ADC therapy decisions.
    Journal
    |
    AXL (AXL Receptor Tyrosine Kinase) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    EGFR expression
    |
    Meiyouheng (becotatug vedotin) • Jiataile (sacituzumab tirumotecan)
    2ms
    RESERVE-HC: Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    2ms
    Becotatug Vedotin for Recurrent/Metastatic Nasopharyngeal Carcinoma (Magic-M001): A Multicenter, Randomized Trial. (PubMed, Ann Oncol)
    Among patients with heavily pretreated and immunotherapy-exposed recurrent or metastatic NPC, becotatug vedotin significantly improved ORR and PFS compared with chemotherapy, with comparable toxicity and encouraging but immature OS results.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    docetaxel • capecitabine • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    2ms
    A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tyvyt (sintilimab) • Yutuo (zimberelimab) • Meiyouheng (becotatug vedotin)
    2ms
    Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, HuiKai Li
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    2ms
    BLOOM-ON: Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=102, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    2ms
    A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
    New P2 trial
    |
    IL2 (Interleukin 2)
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    2ms
    PRAD2: Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Anhui Provincial Cancer Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    3ms
    Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations (clinicaltrials.gov)
    P2/3, N=164, Not yet recruiting, Sir Run Run Shaw Hospital
    New P2/3 trial • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR positive
    |
    cisplatin • gemcitabine • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    3ms
    GATEWAY: Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study (clinicaltrials.gov)
    P2, N=42, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    3ms
    Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Lepu Biopharma Co., Ltd.
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)